Form 4: Edwards Lifesciences CVP Sells Shares Under 10b5-1 Plan

Edwards Lifesciences CVP Daniel J. Lippis sold 1,019 shares of common stock for $85.7037 per share, following an option exercise, under a pre-arranged 10b5-1 trading plan.

Summary

• Daniel J. Lippis, CVP, TAVR at Edwards Lifesciences Corp, executed transactions on January 9, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on July 30, 2025.
• Lippis acquired 1,019 shares of common stock by exercising employee stock options at a price of $59.2567 per share.
• Immediately following the acquisition, Lippis disposed of 1,019 shares of common stock at a weighted average sale price of $85.7037 per share.
• The sale price for the disposition ranged from $85.45 to $85.95.
• Following these transactions, Lippis beneficially owns 22,001.9103 shares of common stock directly.
• Lippis also holds 4,076 derivative securities (employee stock options) directly.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. While an insider sale can be seen negatively, the execution under a 10b5-1 plan mitigates concerns about opportunistic selling. It's a routine part of executive compensation and personal financial management, not indicative of company-specific negative news.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than a reaction to new, non-public information, which can mitigate concerns about opportunistic insider selling.

Negatives

• An insider sale, even under a 10b5-1 plan, represents a reduction in direct ownership by a key executive, which some investors might interpret cautiously.

Risks

• Potential for misinterpretation of insider sales by the market, despite the transparency provided by the Rule 10b5-1 plan.

Future Outlook

NA

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.
• The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction and does not provide specific insights into broader industry trends or competitive landscape for Edwards Lifesciences. It reflects an individual executive's personal financial planning.

Stakeholder Impact

• Shareholders: The sale by a CVP could be perceived negatively by some, but the context of a 10b5-1 plan suggests it is a planned liquidity event rather than a signal of lack of confidence in the company's future. The impact is likely minimal given the routine nature of such disclosures.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction (option exercise and sale) executed under a pre-arranged Rule 10b5-1 trading plan. Such transactions are common for executives managing their personal finances and compensation. It does not provide new material information about the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Therefore, the filing itself does not alter the fundamental investment thesis for Edwards Lifesciences, leading to a 'hold' recommendation based solely on this specific disclosure.

Keywords

Edwards Lifesciences, EW, Insider Trading, Form 4, Stock Option Exercise, Stock Sale, 10b5-1 Plan, Daniel J. Lippis, Corporate Officer, TAVR